Quadrivalent inactivated influenza vaccine - Adimmune Corporation

Drug Profile

Quadrivalent inactivated influenza vaccine - Adimmune Corporation

Alternative Names: ADIMFLU-S(QIS)- Adimmune; Tetravalent influenza vaccine - Adimmune

Latest Information Update: 26 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Adimmune Corporation
  • Developer Adimmune Corporation; Protein Sciences Corporation
  • Class Anti-infectives; Influenza virus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Influenza virus infections

Most Recent Events

  • 10 May 2017 Adimmune Corporation completes a phase III trial in Influenza virus infections (Prevention) in Belgium (IM)
  • 10 May 2017 Registered for Influenza virus infections (Prevention) in Taiwan (IM)
  • 10 May 2017 Adimmune plans a clinical trial for Influenza virus infections (Prevention) in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top